JAMES, page-8

Last year, Garner promised positive news during the first half of 2021.
He delivered.
He has subsequently said that there will be encouraging news during the second half of 2021.
Having previously established his credibility, there is no need for him to publicize the company further.
Just deliver on the science.
The share price will take care of itself.
And if in the absence of management hyping Kazia "we go down again"...buy more.
From the standpoint of investors seeking a huge gain rather than those who desire a short term profit, Garner has adopted the correct strategy.
Through the decades, I have witnessed countless biotech executives beclown themselves by pumping their shares.
Kazia is conducting itself as a serious methodical pharmaceutical organization, and that approach will eventually pay off in a big way.
Hey, it already has...the stock has more than tripled.
Patience.